Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

J. Freedland, Stephen; Luz, Murilo; De Giorgi, Ugo; Gleave, Martin; Gotto, Geoffrey; Pieczonka, Christopher; P. Haas, Gabriel; Kim, Choung‐Soo; Backhaus, M.; Rannikko, Antti; Tarazi, Jamal; Sridharan, Swetha; Sugg, Jennifer; Tang, Yiyun; Tutrone, Ronald; Venugopal, Balaji; Villers, Arnauld; H. Woo, Henry; Zohren, Fabian; D. Shore, Neal

doi:10.1056/nejmoa2303974

Public

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

Published in New England Journal of Medicine • Oct 18, 2023

Authors:

Stephen J. Freedland

Murilo Luz

Ugo De Giorgi

Abstract

BACKGROUND: Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown. METHODS...

Subject

Medicine

Enzalutamide

Prostate cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!